Case series
| 1
| 2
| 3
| 4
| 5
| 6
| 7
| 8
| 9
| 10
| 11
| 12
| 13
| 14
| 15
| 16
| 17
| 18
| 19
| 20
|
Ref
| [7]
| [8]
| [9]
| [9]
| [10]
| [11]
| [12]
| [13]
| [14]
| [15]
| [16]
| [17]
| [4]
| [18]
| [18]
| [19]
| [20]
| [21]
| [21]
| Our case
|
Age
| 46
| 31
| 17
| 29
| 17
| 28
| 63
| 57
| 36
| 46
| 63
| 38
| 32
| 35
| 30
| 49
| 41
| 36
| 49
| 25
|
Gender
| M
| M
| F
| F
| M
| M
| M
| F
| M
| M
| M
| M
| M
| M
| F
| M
| M
| M
| M
| M
|
Clinical
Features
| Gait, sensory disturbance, dysuria
| Sensory disturbance,
paraparesis
| Paraparesis,
sensory disturbance, urinary retention
| Numbness, sensory disturbance, paraparesis
| Paraplegia
| Chorioretinitis, spastic paraparesis
| Sensory deficit, weakness, urinary disturbance
| Paraplegia, urinary retention
| Pain,
paraparesis
| Numbness, pain
| Pain,
weakness
| Pain, weakness, numbness, retained urination
| Tingling, numbness
| Acute transverse myelitis
| Acute transverse myelitis
| Gait, paresthesia, loss of pain and temperature, urinary retention
| Unconscious, numbness
| Paresthesia, ascending paresis in inferior limbs
| Loss of bilateral strength, sensory impairment
| Sensory disturbance,numbness
|
Duration
| 2 weeks
| 10 days
| 8 days
| 9 months
| NA
| 180 days
| 60 days
| 3 days
| 4 months
| 7 days
| 12 days
| 4 months
| 4 months
| 2 weeks
| 1
month
| 2 weeks
| NA
| NA
| NA
| 7 days
|
High risk behavior
| NA
| +
| +
| +
| NA
| +
| NA
| NA
| NA
| +
| NA
| +
| +
| +
| NA
| +
| +
| NA
| NA
| +
|
HIV infection
| NA
| NA
| NA
| NA
| +
| -
| -
| -
| -
| -
| -
| -
| -
| -
| -
| +
| +
| +
| +
| -
|
Blood VDRL
| NA
| 1:640
| 1:4
| 1:4
| 1:16
| NA
| NA
| 1:8
| Reactive
| 1:64
| 1:16
| RPR (1:128)
| 1:16
| Reactive
| Non-reactive
| Reactive
| RPR+
| NA
| NA
| TRUST+
RPR (1:16)
|
Blood TPHA
| NA
| >1:20480
| Reactive
| Reactive
| FTA-ABS(1:6400)
| NA
| NA
| FTA (3+)
TPHA (2+)
| 1:5120
| 1:81920
| Reactive
| 4+
| 1:160
| 1:5120
| 1:1280
| 1:2560
| +
| NA
| NA
| +
|
CSF protein
(mg/dl)
| High
| 94
| 52
| 54
| 106
| 94
| 200
| Normal
| 243
| 72
| 91.70
| 88
| 40
| 123
| 57
| 79
| NA
| NA
| NA
| 148
|
CSF cells
(/uL)
| Pleocytosis
| 120
| 75
| 20
| 180
| 120
| 498
| Pleocytosis
| 346
| 113
| 303
| 18
| 40
| 115
| 170
| 202
| NA
| NA
| NA
| 110
|
CSF VDRL
| Reactive
| 1:80
| Non-Reactive
| Non-Reactive
| NA
| +
| +
| 1:2
| NA
| NA
| Reactive
| 1:16
| +
| Reactive
| Reactive
| NA
| +
| NA
| NA
| NA
|
CSF TPHA
| Reactive
| 1:5120
| Non-Reactive
| Reactive
| FTA-ABS (1:100)
| TPHA+
| NA
| NA
| FTA-ABS
(1:320),
TPHA
(1:640)
| NA
| NA
| NA
| NA
| NA
| NA
| +
| NA
| NA
| NA
| NA
|
Spinal MRI
| High T2 intensity, abnormal Gd-DTPA enhanced
| T3/4 wedge-shaped Gd-DTPA enhanced high intensity, swollen spinal cord
| Below the C4 diffuse high signal, candle guttering appearance
| T1-T11 abnormal signal,
flip-flop sign
| NA
| T6-T8
| LETM, Gadolinium enhancement
| Extensive central high T2 signal, enhancement of the dorsal T8-T9
| Diffuse high T2 signal, flip-flop sign
| T2-T6 high signal, focal Gd-DTPA enhancement
| T6-T11 high signal, focal Gd-DTPA enhancement
| Ventral part on the level of T6–T7
| T5-T12 hyperintense signals
| Spine-cord edema from D4 to conus medullaris
| Spine-cord edema from cervicodorsal up to conus
| High-intensity lesions from C4 to T6
| Spinal cord edema from C3-T1
| Signal impairment in the spinal cord (T2-T12)
| Diffuse hypersignal at several levels
| Longitudinally extensive T2 hyperintensities involving from C7 to T6
|
Treatment
| Antibiotic therapy
| Penicillin,
prednisolone
| Penicillin
| Penicillin, cephalosporins
| Penicillin
| Penicillin, dexamethasone
| Penicillin, dexamethasone
| Antibiotic therapy.
| Penicillin
| Penicillin,
methylprednisolone
| Ceftriaxone, methylprednisolone
| Penicillin, prednisolone
| Penicillin
| Procaine penicillin, Methyl prednisole
| Procaine penicillin, donapezil
| Penicillin potassium, methylprednisolone
| Penicillin
| Penicillin
| Penicillin
| Penicillin
|
Follow-up duration
| NA
| 16 days
| 14 days
| 1 month
| NA
| NA
| 2 years
| 4 weeks
| 28 days
| 21 days
| 30 days
| NA
| 14 days
| 6 months
| Lost
| two weeks
| 1 week
| NA
| NA
| 3 months
|
Status
| Improved
| Improved
| Complete remission
| Improved
| Spasticity
| NA
| Improved
| Non improved
| Improved
| Improved
| Improved
| Positive effect
| NA
| Same
| NA
| Improved
| Improved
| Complete improvement
| Partial improvement
| Improved
|
Repeat CSF finding
| NA
| TPHA
(1:2560),
VDRL
(1:40)
| Cells 9/uL, protein 38mg/dl
| NA
| Non-reactive
| NA
| NA
| NA
| Reduced
| N
| cells 34/uL,
protein 45.4mg/dl
| NA
| NA
| NA
| NA
| NA
| MA
| NA
| NA
| cells 24/uL,
protein 65 mg/dl,
TPPA +, TRUST 1:1.
|
Repeat blood finding
| NA
| TPHA
(1:10240),
VDRL
(1:160)
| NA
| NA
| NA
| NA
| NA
| NA
| NA
| VDRL
(1:16)
| RPR
(1:4)
| RPR
(1:64)
| NA
| NA
| NA
| NA
| NA
| NA
| NA
| TPPA (+), TRUST (1:8)
|
Repeat MRI finding
| Disappearance of intramedullary high intensity areas
| Reduction in the intensity of lesions
| Reduction in the intensity of lesions
| Reduction in the intensity of lesions
| NA
| NA
| NA
| Disappearance of the high signal lesion on T2-weighted images
| Gadolinium enhancement disappeared, the high signal intensity diminished
| NA
| Reduction in the intensity of lesions
| NA
| NA
| NA
| NA
| Reduction in the size of the cervical and thoracic cord lesions
| NA
| NA
| NA
| Dissolved with three months' follow up
|